Baidu
map

JAMA:股动脉穿刺后止血:血管闭合器不劣于人工按压

2014-11-27 清热解毒2号 丁香园

在美国,经股动脉仍是冠脉造影最常用的穿刺部位,而穿刺后止血方法为通常人工按压。20世纪90年代中期,血管闭合器的出现大大缩短了止血时间和术后活动时间。 然而,许多Meta分析却发现,血管闭合器出现腹股沟血肿和动脉假性动脉瘤等血管并发症的风险高于人工按压,而随机临床试验的规模较小,且只评估该装置的有效性,对安全问题的全面评估排除在外。 为此,来自德国慕尼黑理工大学的Stefanie

在美国,经股动脉仍是冠脉造影最常用的穿刺部位,而穿刺后止血方法为通常人工按压。20世纪90年代中期,血管闭合器的出现大大缩短了止血时间和术后活动时间。

然而,许多Meta分析却发现,血管闭合器出现腹股沟血肿和动脉假性动脉瘤等血管并发症的风险高于人工按压,而随机临床试验的规模较小,且只评估该装置的有效性,对安全问题的全面评估排除在外。

为此,来自德国慕尼黑理工大学的Stefanie Schulz-Schüpke等进行了一项随机临床试验,研究结果在线发表于近日的JAMA

该研究是一项多中心的开放标签的大型随机临床试验,研究者纳入了4524例经股总动脉置入6F鞘管行冠脉造影的患者,随访时间为期30天。主要比较经股动脉途径行诊断性冠脉造影后两种不同止血策略结局的区别:标准人工按压VS血管闭合器(包括血管内和血管外两类装置)。

造影完毕后,患者按1:1:1的比例随机分至血管内血管闭合器组(n=1509)、血管外血管闭合器组(n=1506)和人工按压组(n=1509)。

研究的主要终点为随机化后30天内穿刺点相关血管并发症(非劣效性界值小于2%);次级终点为止血时间、反复人工按压血管闭合器失败。研究者在出院前对4231(91%)例患者穿刺部位进行了彩色多普勒超声检查。

研究发现,血管闭合器组和人工按压组分别有208例(6.9%)和119例患者(7.9%)出现主要终点。血管闭合器组(1min,四分位间距[IQR]0.5-2.0min)的止血时间明显短于人工按压组(10min,IQR 10-15min);血管内血管闭合器(0.5 min,IQR 0.2-1.0min)的止血时间不仅明显少于血管外血管闭合器(2.0min IQR 1.0-2.0),其闭合装置失败的比例明显低于血管外闭合器组。

研究者认为,在经股动脉行冠脉造影患者中,血管闭合器在减少血管穿刺点并发症和止血时间方面不劣于人工按压。

原始出处:

Schulz-Schüpke S1, Helde S2, Gewalt S2, Ibrahim T3, Linhardt M2, Haas K2, Hoppe K4, Böttiger C4, Groha P2, Bradaric C3, Schmidt R5, Bott-Flügel L6, Ott I2, Goedel J2, Byrne RA2, Schneider S3, Burgdorf C2, Morath T2, Kufner S2, Joner M7, Cassese S2, Hoppmann P3, Hengstenberg C1, Pache J4, Fusaro M2, Massberg S8, Mehilli J8, Schunkert H1, Laugwitz KL9, Kastrati A1; Instrumental Sealing of Arterial Puncture Site—CLOSURE Device vs Manual Compression (ISAR-CLOSURE) Trial Investigators.Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial.JAMA. 2014 Nov 19;312(19):1981-7. doi: 10.1001/jama.2014.15305.


您还可以这样阅读:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1651250, encodeId=3822165125016, content=<a href='/topic/show?id=6f9c564499c' target=_blank style='color:#2F92EE;'>#按压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56449, encryptionId=6f9c564499c, topicName=按压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a7424147894, createdName=lisa446, createdTime=Mon Dec 15 12:47:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010590, encodeId=f534201059065, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Dec 29 08:47:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263020, encodeId=650d126302094, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311861, encodeId=cfdf131186125, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
    2014-12-15 lisa446
  2. [GetPortalCommentsPageByObjectIdResponse(id=1651250, encodeId=3822165125016, content=<a href='/topic/show?id=6f9c564499c' target=_blank style='color:#2F92EE;'>#按压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56449, encryptionId=6f9c564499c, topicName=按压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a7424147894, createdName=lisa446, createdTime=Mon Dec 15 12:47:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010590, encodeId=f534201059065, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Dec 29 08:47:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263020, encodeId=650d126302094, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311861, encodeId=cfdf131186125, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1651250, encodeId=3822165125016, content=<a href='/topic/show?id=6f9c564499c' target=_blank style='color:#2F92EE;'>#按压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56449, encryptionId=6f9c564499c, topicName=按压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a7424147894, createdName=lisa446, createdTime=Mon Dec 15 12:47:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010590, encodeId=f534201059065, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Dec 29 08:47:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263020, encodeId=650d126302094, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311861, encodeId=cfdf131186125, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
    2014-11-29 jeanqiuqiu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1651250, encodeId=3822165125016, content=<a href='/topic/show?id=6f9c564499c' target=_blank style='color:#2F92EE;'>#按压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56449, encryptionId=6f9c564499c, topicName=按压)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a7424147894, createdName=lisa446, createdTime=Mon Dec 15 12:47:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2010590, encodeId=f534201059065, content=<a href='/topic/show?id=8abf81e6327' target=_blank style='color:#2F92EE;'>#股动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81763, encryptionId=8abf81e6327, topicName=股动脉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Mon Dec 29 08:47:00 CST 2014, time=2014-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263020, encodeId=650d126302094, content=<a href='/topic/show?id=ebb5631e076' target=_blank style='color:#2F92EE;'>#止血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63170, encryptionId=ebb5631e076, topicName=止血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1311861, encodeId=cfdf131186125, content=<a href='/topic/show?id=21a6e54280e' target=_blank style='color:#2F92EE;'>#穿刺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75428, encryptionId=21a6e54280e, topicName=穿刺)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Sat Nov 29 00:47:00 CST 2014, time=2014-11-29, status=1, ipAttribution=)]
    2014-11-29 rgjl

相关资讯

Diabetes Care:空气污染或参与糖尿病血管并发症

  一项研究表明,在印度2型糖尿病患者中空气污染可能促发全身性炎症反应,可能在糖尿病血管并发症中起一定作用。论文于2012年11月19日在线发表于《糖尿病护理》(Diabetes Care)杂志。   此项横断面研究在2型糖尿病患者中对每日系列大气污染数据和血浆C反应蛋白(CRP)浓度进行了相关性评估。对年龄、性别、体质指数(BMI)、血红蛋白、空腹血糖、抗炎活性药物治疗、季节、温度和

T2DM患者口服降糖药失效后应尽快胰岛素治疗

  发表于2012年第6期《中国糖尿病杂志》上的一项研究表明, 2型糖尿病(T2DM)患者口服降糖药(OADs)失效后应尽快采用注射胰岛素、加强运动、控制饮食、减轻体重等干预治疗,可明显减少血管并发症发生。   研究选取了住院及门诊患者453例,分为治疗组(232例)和对照组(221例)。治疗组注射胰岛素,严格控制FPG在6mmol/L左右;控制饮食,每日摄入热卡25kcal/kg;每

JAMA:GCK突变者血糖高但血管并发症发生率较低

一项英国研究显示,尽管葡萄糖激酶(GCK)突变者自出生后空腹血糖水平即轻度升高,但此人群发生微血管和大血管并发症的几率较低。文章1月15日在线发表于《美国医学会杂志》(JAMA)。 研究纳入99例携带GCK突变基因的受试者、91例无糖尿病无基因突变的对照者和83例早发2型糖尿病患者(诊断糖尿病时年龄为45岁或更小)。结果显示,这三组患者的平均糖化血红蛋白(HbA1c)分别为6.9

Diabetologia:MMP-10或参与糖尿病微血管并发症的发生

MMP-10与糖尿病肾病和视网膜病变的关系 金属蛋白酶-10(MMP-10)在1型糖尿病中的作用尚不清楚。为了探讨金属蛋白酶-10是否在糖尿病肾病和糖尿病视网膜病变发生和发展中发挥作用,来自西班牙纳瓦拉大学Nieves Díez教授及其团队进行了一项研究,该研究发现MMP-10参与1型糖尿病微血管并发症的发生。该研究结果发表在2013年12月的Diabetologia杂志上。 

Baidu
map
Baidu
map
Baidu
map